Because spironolactone and the S3E mutation yield parallel effects on Cx43 distribution and arrhythmia susceptibility [9,11], one can speculate that the Cx43-pS365 isoform, protected by the hormone inhibitor, is also protected in the transgenic S3E hearts. The gene discussed is GJA1; the disease is Arrhythmia.